Governor Signed
Summary
The bill broadens the situations in which a patient with a serious or terminal illness can obtain an investigational medicine or device, updating definitions of eligible illnesses, patients, dosage forms, and terminal conditions. It also requires manufacturers who provide such treatments outside of formal clinical trials to report usage details to the state health committee within a set timeframe. These changes aim to give patients more options while giving the state better oversight.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Topics
Track this bill
Get real-time alerts when SB 222 changes status, plus AI-powered summaries and stage predictions.
Sign up free